Badges [ 3 ] [-]
Memberships [ 1 ] [+]
Ideas Contributed [ 2 ] [+]
There are new RNA based genetic differences in people that are strong biomarkers of cancer risk, and need additional study in appropriate clinical trials. Such mutations can be modified by lifestyle, and afford a true opportunity for prevention.
There is a great need to find biomarkers predicting response to developing immune therapies. Germ-line microRNA binding site mutations are a recently discovered, powerful new type of biomarker of response to cancer therapy, including immune therapy.